Cargando…

Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression

Non-small cell cancer (NSCLC) has been identified with a great variation of mutations that can be surveyed during disease progression. The aim of the study was to identify and monitor lung cancer-specific mutations incidence in cell-free DNA as well as overall plasma cell-free DNA load by means of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sestokaite, Agne, Gedvilaite, Vaida, Cicenas, Saulius, Sabaliauskaite, Rasa, Jarmalaite, Sonata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138687/ https://www.ncbi.nlm.nih.gov/pubmed/37108122 http://dx.doi.org/10.3390/ijms24086958

Ejemplares similares

A Systematic Review of Candidate Genes for Major Depression
por: Norkeviciene, Audrone, et al.
Publicado: (2022)

Urinary DNA as a Tool for Germline and Somatic Mutation Detection in Castration-Resistant Prostate Cancer Patients
por: Januskevicius, Tomas, et al.
Publicado: (2023)

Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients
por: Žilovič, Diana, et al.
Publicado: (2023)

Cell-free DNA in non-small cell lung cancer
por: Gedvilaitė, Vaida, et al.
Publicado: (2017)

Future Screening Prospects for Ovarian Cancer
por: Žilovič, Diana, et al.
Publicado: (2021)

Lung Cancer Survival in Lithuania: Changes by Histology, Age, and Sex From 2003-2007 to 2008-2012
por: Gedvilaitė, Vaida, et al.
Publicado: (2019)

The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer
por: Vaicekauskaitė, Ieva, et al.
Publicado: (2022)

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay
por: Guo, Qiao-mei, et al.
Publicado: (2019)

Recurrent Germline BRCA2 Gene Mutation in Lithuanian Family
por: Sadzevičienė, Ieva, et al.
Publicado: (2020)

In silico error correction improves cfDNA mutation calling
por: Kim, Chang Sik, et al.
Publicado: (2019)

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019)

Synchronous endometrial and ovarian cancer: A case report
por: Žilovič, Diana, et al.
Publicado: (2023)

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients
por: Liu, Haiyan E., et al.
Publicado: (2020)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019)

ARID1A, NOTCH and WNT Signature in Gynaecological Tumours
por: Vaicekauskaitė, Ieva, et al.
Publicado: (2023)

Fusion sequencing via terminator‐assisted synthesis (FTAS‐seq) identifies TMPRSS2 fusion partners in prostate cancer
por: Drazdauskienė, Ugnė, et al.
Publicado: (2023)

The use of cell free DNA (cfDNA) for mutational screening of multiple myeloma
por: Marivel, A-M Joëlle, et al.
Publicado: (2023)

Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC
por: Chen, Xuejing, et al.
Publicado: (2021)

Analysis of Intrinsic Breast Cancer Subtypes: The Clinical Utility of Epigenetic Biomarkers and TP53 Mutation Status in Triple-Negative Cases
por: Sadzeviciene, Ieva, et al.
Publicado: (2022)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022)

cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Plasma cfDNA for the Diagnosis and Prognosis of Colorectal Cancer
por: Wu, Zhiwei, et al.
Publicado: (2022)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Verzè, Michela, et al.
Publicado: (2021)

Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
por: Ntzifa, Aliki, et al.
Publicado: (2021)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
por: Zhao, Xiaolong, et al.
Publicado: (2021)

Vitamin D and VDR Gene Polymorphisms’ Association with Rheumatoid Arthritis in Lithuanian Population
por: Punceviciene, Egle, et al.
Publicado: (2021)

Analysis of Epigenetic Changes in Vitamin D Pathway Genes in Rheumatoid Arthritis Patients
por: Puncevičienė, Eglė, et al.
Publicado: (2022)

Comparison of the source and prognostic utility of cfDNA in trauma and sepsis
por: Jackson Chornenki, Nicholas L., et al.
Publicado: (2019)

Novel technologies in cfDNA analysis and potential utility in clinic
por: Li, Jie, et al.
Publicado: (2021)

cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
por: Gerard, Laura, et al.
Publicado: (2021)

cfDNA changes for monitoring of targeted therapy in a primary EGFR mutation lung adenocarcinoma
por: He, Qiong, et al.
Publicado: (2020)

Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer
por: Fujita, Kazutaka, et al.
Publicado: (2021)

CfDNA Measurement as a Diagnostic Tool for the Detection of Brain Somatic Mutations in Refractory Epilepsy
por: Mayo, Sonia, et al.
Publicado: (2022)

Evaluation of the Analytical Performance of Oncomine Lung cfDNA Assay for Detection of Plasma EGFR Mutations
por: Cho, Yong Gon, et al.
Publicado: (2023)

Decreased expression of MT1E is a potential biomarker of prostate cancer progression
por: Demidenko, Rita, et al.
Publicado: (2017)

Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC
por: Jiang, Tao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2utvflhfp8mrieqdv2kfv3ntjh